The critical role of the class III histone deacetylase SIRT2 in stabilizing N-Myc oncoprotein. Cancer is the commonest cause of death from disease in children. Neuroblastoma is the commonest solid tumor in early childhood. This project will investigate the critical roles of SIRT2 protein in increasing the expression of N-Myc oncoprotein and consequently inducing neuroblastoma, and SIRT2 inhibitors as anticancer agents.
Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.
The Centre will enhance Australian clinical immunisation research and training, focussing upon clinical questions with translatable outcomes not easily addressed by industry. Optimal immunisation and interventions to maximise uptake of existing and new vaccines in high risk patient groups, such as children with cancer, immigrants, children with chronic diseases and adolescents will be studied. New vaccine trials, innovative use of existing vaccines, systematic collection of vaccine failure data, ....The Centre will enhance Australian clinical immunisation research and training, focussing upon clinical questions with translatable outcomes not easily addressed by industry. Optimal immunisation and interventions to maximise uptake of existing and new vaccines in high risk patient groups, such as children with cancer, immigrants, children with chronic diseases and adolescents will be studied. New vaccine trials, innovative use of existing vaccines, systematic collection of vaccine failure data, and targeted epidemiology and disease modelling vaccine preventable disease will also allow a broad program of research, enabling training and mentoring of young clinical nurse and physician researchers. Collaborations with existing national immunisation, infectious diseases and research institutions will allow maximal effectiveness of clinical studies.Read moreRead less
A Transmission-Blocking Vaccine To Prevent Toxoplasmosis
Funder
National Health and Medical Research Council
Funding Amount
$850,225.00
Summary
Toxoplasma gondii causes a globally important zoonotic disease. It is transmitted by cats, and finds its way into our food chain via infected meat and contaminated water. We have used a unique functional genomics pipeline to discover proteins crucial for reproduction of Toxoplasma in the cat. We will now test combinations of these proteins to immunise cats and prove that we can develop a vaccine that blocks transmission of this highly significant parasitic disease.
Immunomodulatory Vaccines In The Treatment Of Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$678,899.00
Summary
Peanut allergy is the most common cause of food-induced anaphylactic reactions in Australia and is a major burden to our healthcare system. Current clinical practice advice dietary avoidance to prevent fatal anaphylactic responses. We propose the use of an immunomodulatory vaccine to re-write the immune response to peanut antigens, from an allergic to a tolerant phenotype. This study will provide novel insights into rational approaches for manipulating immune memory to food allergens.
Immunisation In Under Studied And Special Risk Populations: Closing The Gap In Knowledge Through A Multidisciplinary Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,499,969.00
Summary
Much of the vaccine research which informs national policy is conducted by the pharmaceutical industry or by government. However, there are critical research gaps in special-risk and under-served populations where targeted research is not commercially viable. These include research in the extremes of age, Indigenous Australians, migrants, refugees, immunosuppressed and traveller populations. This CRE will address research gaps in such populations, which have not been addressed elsewhere, using n ....Much of the vaccine research which informs national policy is conducted by the pharmaceutical industry or by government. However, there are critical research gaps in special-risk and under-served populations where targeted research is not commercially viable. These include research in the extremes of age, Indigenous Australians, migrants, refugees, immunosuppressed and traveller populations. This CRE will address research gaps in such populations, which have not been addressed elsewhere, using novel, multidisciplinary methods.Read moreRead less
Group A Streptococcal Human Challenge Study: Accelerating Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$2,018,741.00
Summary
Infection with group A streptococcus (GAS) is a major cause of morbidity and mortality worldwide, including in the Aboriginal population of Australia. Concerted efforts for vaccine development have been hampered by the absence of a suitable animal model. To address this critical knowledge gap we propose to develop a controlled human infection model of GAS infection. This model will provide a direct pathway for the future appraisal of novel GAS vaccines.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100082
Funder
Australian Research Council
Funding Amount
$180,000.00
Summary
FACSAria III - Fluorescence activated cell sorter. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. The FACSAria III cell sorter will be used to establish a core facility for sorting cells. The outcomes from using this technology are a better understanding cellular and genetic understanding of cancer, respiratory diseases, reproduction and ....FACSAria III - Fluorescence activated cell sorter. Flow cytometry is a technique for counting and examining microscopic particles, such as cells and chromosomes, by suspending them in a stream of fluid and passing them by an electronic detection apparatus. The FACSAria III cell sorter will be used to establish a core facility for sorting cells. The outcomes from using this technology are a better understanding cellular and genetic understanding of cancer, respiratory diseases, reproduction and birth. Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE190100668
Funder
Australian Research Council
Funding Amount
$422,574.00
Summary
Cysteamine dioxygenases: novel oxygen sensors implicated in hypoxia? This project aims to characterise and manipulate a novel oxygen sensing system, the cysteamine dioxygenases, to help understand how mammalian cells respond to low oxygen concentrations, a condition known as hypoxia. A number of the world’s most destructive diseases can impair oxygen delivery, altering biochemical landscapes. By understanding how cells respond to fluctuations in oxygen, the project expects to develop effective m ....Cysteamine dioxygenases: novel oxygen sensors implicated in hypoxia? This project aims to characterise and manipulate a novel oxygen sensing system, the cysteamine dioxygenases, to help understand how mammalian cells respond to low oxygen concentrations, a condition known as hypoxia. A number of the world’s most destructive diseases can impair oxygen delivery, altering biochemical landscapes. By understanding how cells respond to fluctuations in oxygen, the project expects to develop effective methods to treat these detrimental conditions. Characterisation of the cysteamine dioxygenases could establish a novel mechanism by which cells monitor changes in oxygen, assisting in understanding hypoxia and disease. The project will also enable new cysteine initiating substrates to be identified, allowing the full impact of this regulatory process to be appreciated in mammals.Read moreRead less
The Role Of Capsid Protein Nucleolar Localisation In Chikungunya Virus: Implications For Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$520,520.00
Summary
Chikungunya virus (CHIKV) is a globally widespread mosquito-borne alphavirus capable of causing considerable human morbidity and mortality. With no CHIKV vaccine or antiviral available this proposal aims to develop a live attenuated CHIKV vaccine, rationally designed by investigating the host cell nucleolar trafficking of CHIKV capsid protein. This vaccine has the potential to provide cross-protection against additional arthritogenic alphaviruses endemic to Australia such as Ross River virus.